Review



anti src  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc anti src
    Anti Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 343 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FoxD3+Rabbit+mAb/pm41499010-148-1-7
    Average 96 stars, based on 343 article reviews
    anti src - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: Neogenin-loss in neural crest cells results in persistent hyperplastic primary vitreous formation
    Article Snippet: The primary antibodies used in the experiments were anti-PH3 (1:500, Millipore), anti-Ki67 (1:400, Millipore), anti-MiTF (1:400, Abcam), anti-AP2 β (1:300, Cell Signaling Technology), anti-CD31 (1:500, BD), anti-PDGFR β (1:500, Abcam), anti-Sox9 (1:300, Millipore), anti-FoxD3 (1:300, Cell Signaling Technology), and anti-Sox10 (1:300, Cell Signaling Technology).

    Article Title: FOXD3 promotes homologous recombination repair and genomic stability by facilitating MRE11-mediated DNA end resection.
    Article Snippet: Antibodies The following antibodies were used in this study: anti-FLAG M2 (Sigma-Aldrich), anti-FOXD3 (2019S; Cell Signaling Technology, Danvers, USA), anti-FOXD3 (27878-1-AP; Proteintech, Wuhan, China), anti-GST (66001-2-Ig; Proteintech), anti-ACTIN (AC026; ABclonal, Wuhan, China), anti-PARP1 (13371-1-AP; Proteintech), anti-BRCA1 (22362-1-AP; Proteintech), anti-RPA32 (10412-1-AP; Proteintech), anti-RPA32 (A300-244A; Bethyl, Montgomery, USA), anti-pRPA32 S33 (A300-246A; Bethyl), anti-ATM (A300-299A; Bethyl), anti-pATM S1981 (ab82192; Abcam, Cambridge, UK), anti-gamma H2AX (A300-081A; Bethyl), anti-gamma H2AX (80312S; Cell Signaling Technology), anti-IdU (347580; BD Biosciences, Franklin Lakes, USA), anti-Histone H3 (ab176842; Abcam), anti-RAD51 (ab133534; Abcam), anti-MRE11 (Genetex, GTX70212), anti-RAD50 (A300-185A; Bethyl), anti-NBS1 (14956S; Cell Signaling Technology), and anti-pCHK2 T68 (2661S; Cell Signaling Technology).

    Article Title: FOXD3 promotes homologous recombination repair and genomic stability by facilitating MRE11-mediated DNA end resection
    Article Snippet: The following antibodies were used in this study: anti-FLAG M2 (Sigma-Aldrich), anti-FOXD3 (2019S; Cell Signaling Technology, Danvers, USA), anti-FOXD3 (27878-1-AP; Proteintech, Wuhan, China), anti-GST (66001-2-Ig; Proteintech), anti-ACTIN (AC026; ABclonal, Wuhan, China), anti-PARP1 (13371-1-AP; Proteintech), anti-BRCA1 (22362-1-AP; Proteintech), anti-RPA32 (10412-1-AP; Proteintech), anti-RPA32 (A300-244A; Bethyl, Montgomery, USA), anti-pRPA32 S33 (A300-246A; Bethyl), anti-ATM (A300-299A; Bethyl), anti-pATM S1981 (ab82192; Abcam, Cambridge, UK), anti-gamma H2AX (A300-081A; Bethyl), anti-gamma H2AX (80312S; Cell Signaling Technology), anti-IdU (347580; BD Biosciences, Franklin Lakes, USA), anti-Histone H3 (ab176842; Abcam), anti-RAD51 (ab133534; Abcam), anti-MRE11 (Genetex, GTX70212), anti-RAD50 (A300-185A; Bethyl), anti-NBS1 (14956S; Cell Signaling Technology), and anti-pCHK2 T68 (2661S; Cell Signaling Technology).



    Similar Products

    96
    Cell Signaling Technology Inc anti src
    Anti Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FoxD3+Rabbit+mAb/pm41499010-148-1-7
    Average 96 stars, based on 1 article reviews
    anti src - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    95
    R&D Systems foxd3
    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), <t>FOXD3</t> (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.
    Foxd3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/Human+Islet-1+Antibody/bio_rxiv__64898__2025__12__22__696129-323-10-22
    Average 95 stars, based on 1 article reviews
    foxd3 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc rabbit anti phospho tau ser404
    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), <t>FOXD3</t> (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.
    Rabbit Anti Phospho Tau Ser404, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FoxD3+Rabbit+mAb/10__4103_slash_nrr__nrr___d___25___00006-153-19-25
    Average 96 stars, based on 1 article reviews
    rabbit anti phospho tau ser404 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology antibodies against foxd3
    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), <t>FOXD3</t> (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.
    Antibodies Against Foxd3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FOXD3+Antibody/pmc10861880__pnas__2312861121__sapp-87-10-13
    Average 93 stars, based on 1 article reviews
    antibodies against foxd3 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology foxd3
    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), <t>FOXD3</t> (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.
    Foxd3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FOXD3+Antibody/pmc10861880__pnas__2312861121__sapp-53-35-38
    Average 93 stars, based on 1 article reviews
    foxd3 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc anti foxd3
    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), <t>FOXD3</t> (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.
    Anti Foxd3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/pmc12616725-38-11-13
    Average 86 stars, based on 1 article reviews
    anti foxd3 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology 5g9b10
    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), <t>FOXD3</t> (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.
    5g9b10, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FOXD3+Antibody/pm39260321-77-21-22
    Average 93 stars, based on 1 article reviews
    5g9b10 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology forkhead box d3 foxd3
    Fig. 6. <t>FOXD3</t> activated the transcription of SERCA2a. (A) Western blot analysis of FOXD3 in H9c2 cells transfected with FOXD3 overexpression plasmid or control vector. (B) The effect of SERCA2a mRNA expression in H9c2 cells transfected with FOXD3 overexpressing plasmid or control vector. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; ** P<0.01, vs vector group. (C and D) The effect of SERCA2a protein expression in H9c2 cells transfected with FOXD3 overexpressing plasmid or control vector. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; * P<0.05, vs vector group. (E) The effects of FOXD3 overexpression on SERCA2a promoter relative activity in the 293 t cells. n = 3; The data were expressed as mean ± SEM and analyzed using One-way ANOVA follow by Tukey post-hoc tests; *** P<0.001, vs vector group. (F) Western blot analysis of FOXD3 in H9c2 cells transfected with FOXD3 siRNA. (G) The effect of CAL on SERCA2a mRNA level after FOXD3 silence. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; * P<0.05, CAL vs CAL+FOXD3 siRNA.
    Forkhead Box D3 Foxd3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+foxd3/FOXD3+Antibody/pm39260321-77-16-22
    Average 93 stars, based on 1 article reviews
    forkhead box d3 foxd3 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), FOXD3 (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.

    Journal: bioRxiv

    Article Title: In vivo human embryonic spinal cord atlas validates stem cell–derived human dorsal interneurons and reveals ASD spinal signatures

    doi: 10.64898/2025.12.22.696129

    Figure Lengend Snippet: (A, B) EBs were generated at day 0 after either d4 (A) or d10 (B) NMP formation and then treated with RA for 10 days (control). In the experimental samples, BMPs were added at day 1 (BMP4+1), day 2 (BMP4+2) or day 4 (BMP4+4) after EB formation, until day 10. Samples were further differentiated for 6 days and then processed for immunohistochemistry (IHC). (C) EBs were labeled with antibodies against LHX2 (dI1, green), FOXD3 (dI2, white), ISL1 (dI3, red) and DAPI (all nuclei, blue). (D, E) Quantification of EBs formed from either d4 (D) or d10 (E) NMPs, suggests that dI1s form robustly from the BMP4+1 condition for both d4 and d10 NMPs. In contrast, dI3s form most robustly from BMP4+4 condition for d4 NMPs and the BMP4+1 condition for d10 NMPs. Probability of similarity between control and experimental groups: * p<0.05, ** p<0.005, *** p<0.0005; two-way ANOVA.

    Article Snippet: The following antibodies were used: LHX2 (mouse; DSHB, PCRP-LHX2-1C11; 1:50), FOXD3 (guinea pig, a gift from Thomas Mueller, Germany, 1:10,000), ISL1 (goat; R&D systems, AF1837; 1:500), PAX2 (rabbit; Invitrogen, 71-6000; 1:500), LMX1B (guinea pig; Thomas Muller Lab), LHX1/5 (mouse; DSHB, 4F2; 1:50) for 12–14 hours (overnight) at 2–8°C in a humidified chamber.

    Techniques: Generated, Control, Immunohistochemistry, Labeling

    Fig. 6. FOXD3 activated the transcription of SERCA2a. (A) Western blot analysis of FOXD3 in H9c2 cells transfected with FOXD3 overexpression plasmid or control vector. (B) The effect of SERCA2a mRNA expression in H9c2 cells transfected with FOXD3 overexpressing plasmid or control vector. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; ** P<0.01, vs vector group. (C and D) The effect of SERCA2a protein expression in H9c2 cells transfected with FOXD3 overexpressing plasmid or control vector. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; * P<0.05, vs vector group. (E) The effects of FOXD3 overexpression on SERCA2a promoter relative activity in the 293 t cells. n = 3; The data were expressed as mean ± SEM and analyzed using One-way ANOVA follow by Tukey post-hoc tests; *** P<0.001, vs vector group. (F) Western blot analysis of FOXD3 in H9c2 cells transfected with FOXD3 siRNA. (G) The effect of CAL on SERCA2a mRNA level after FOXD3 silence. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; * P<0.05, CAL vs CAL+FOXD3 siRNA.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: Calotropin attenuates ischemic heart failure after myocardial infarction by modulating SIRT1/FOXD3/SERCA2a pathway.

    doi: 10.1016/j.biopha.2024.117384

    Figure Lengend Snippet: Fig. 6. FOXD3 activated the transcription of SERCA2a. (A) Western blot analysis of FOXD3 in H9c2 cells transfected with FOXD3 overexpression plasmid or control vector. (B) The effect of SERCA2a mRNA expression in H9c2 cells transfected with FOXD3 overexpressing plasmid or control vector. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; ** P<0.01, vs vector group. (C and D) The effect of SERCA2a protein expression in H9c2 cells transfected with FOXD3 overexpressing plasmid or control vector. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; * P<0.05, vs vector group. (E) The effects of FOXD3 overexpression on SERCA2a promoter relative activity in the 293 t cells. n = 3; The data were expressed as mean ± SEM and analyzed using One-way ANOVA follow by Tukey post-hoc tests; *** P<0.001, vs vector group. (F) Western blot analysis of FOXD3 in H9c2 cells transfected with FOXD3 siRNA. (G) The effect of CAL on SERCA2a mRNA level after FOXD3 silence. n = 3; The data were expressed as mean ± SD and analyzed using One-way ANOVA follow by Tukey post-hoc tests; * P<0.05, CAL vs CAL+FOXD3 siRNA.

    Article Snippet: Then they were incubated with primary antibodies against SERCA2a (1:1000, A11692, ABclonal), SIRT1 (1:1000, A0230, ABclonal), forkhead Box D3 (FOXD3) (1:1000, 5G9B10, Santa Cruz), GAPDH (1:10000, AC010, ABclonal), and β-Actin (1:100000, A026, ABclonal).

    Techniques: Western Blot, Transfection, Over Expression, Plasmid Preparation, Control, Expressing, Activity Assay

    Fig. 7. CAL promoted SERCA2a transcription via SIRT1-dependent deacetylation of FOXD3 in HF post-MI. (A) The effect of CAL on FOXD3 expression in the presence of EX527 in LAD-induced HF rat heart tissue. (B) The effect of CAL on FOXD3 expression in the presence of EX527 in OGD/R-induced H9c2 cells. (C-F) The effect of CAL on the FOXD3 location. ##P<0.01, ### P<0.001, vs control group; ** P<0.01, vs OGD/R group. (G) Immunofluorescence images for FOXD3. (H)The effect of CAL on FOXD3 acetylation in the presence of EX527 in LAD-induced HF rat heart tissue. (I) The effect of CAL on FOXD3 acetylation in the presence of EX527 in OGD/ R-induced H9c2 cells.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: Calotropin attenuates ischemic heart failure after myocardial infarction by modulating SIRT1/FOXD3/SERCA2a pathway.

    doi: 10.1016/j.biopha.2024.117384

    Figure Lengend Snippet: Fig. 7. CAL promoted SERCA2a transcription via SIRT1-dependent deacetylation of FOXD3 in HF post-MI. (A) The effect of CAL on FOXD3 expression in the presence of EX527 in LAD-induced HF rat heart tissue. (B) The effect of CAL on FOXD3 expression in the presence of EX527 in OGD/R-induced H9c2 cells. (C-F) The effect of CAL on the FOXD3 location. ##P<0.01, ### P<0.001, vs control group; ** P<0.01, vs OGD/R group. (G) Immunofluorescence images for FOXD3. (H)The effect of CAL on FOXD3 acetylation in the presence of EX527 in LAD-induced HF rat heart tissue. (I) The effect of CAL on FOXD3 acetylation in the presence of EX527 in OGD/ R-induced H9c2 cells.

    Article Snippet: Then they were incubated with primary antibodies against SERCA2a (1:1000, A11692, ABclonal), SIRT1 (1:1000, A0230, ABclonal), forkhead Box D3 (FOXD3) (1:1000, 5G9B10, Santa Cruz), GAPDH (1:10000, AC010, ABclonal), and β-Actin (1:100000, A026, ABclonal).

    Techniques: Expressing, Control, Immunofluorescence

    Fig. 8. Calotropin improved cardiac function and prevented adverse ventric ular remodeling in ischemic heart failure after MI via the SIRT1/FOXD3/SER CA2a pathway.

    Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    Article Title: Calotropin attenuates ischemic heart failure after myocardial infarction by modulating SIRT1/FOXD3/SERCA2a pathway.

    doi: 10.1016/j.biopha.2024.117384

    Figure Lengend Snippet: Fig. 8. Calotropin improved cardiac function and prevented adverse ventric ular remodeling in ischemic heart failure after MI via the SIRT1/FOXD3/SER CA2a pathway.

    Article Snippet: Then they were incubated with primary antibodies against SERCA2a (1:1000, A11692, ABclonal), SIRT1 (1:1000, A0230, ABclonal), forkhead Box D3 (FOXD3) (1:1000, 5G9B10, Santa Cruz), GAPDH (1:10000, AC010, ABclonal), and β-Actin (1:100000, A026, ABclonal).

    Techniques: